Mosaicism is the presence of cells within an organism that have a different genetic composition despite deriving from a single zygote. The consequence of this depends on the number and type of cells that are affected as well as the specific DNA involved. There are several diseases where mosaicism is known to occur, but the currently observed frequency is presumably an underestimation due to the difficulty of detecting changes in only a percentage of cells. Recent advances in technology have provided a greater insight into the frequency and mechanisms of mosaicism in all forms. This review will cover the different techniques that can be used for detecting copy number variation (CNV) in mosaic form, and describe some of the insights that different diseases have given on the true frequencies and mechanisms responsible for somatic rearrangements. It will conclude with a discussion of the implications of the recent description of CNV in identical twins, and what remains to be elucidated in the world of mosaic CNV.

1.
Armour JA, Sismani C, Patsalis PC, Cross G: Measurement of locus copy number by hybridization with amplifiable probes. Nucleic Acids Res 28:605–609 (2000).
2.
Armour JA, Barton DE, Cockburn DJ, Taylor GR: The detection of large deletions or duplications in genomic DNA. Hum Mutat 20:325–337 (2002).
3.
Bakker E, Van Broeckhoven C, Bonten EJ, van de Vooren MJ, Veenema H, et al: Germline mosaicism and Duchenne muscular dystrophy mutations. Nature 329:554–556 (1987).
4.
Bakker E, Veenema H, den Dunnen JT, van Broeckhoven C, Grootscholten PM, et al: Germinal mosaicism increases the recurrence risk for ‘new’ Duchenne muscular dystrophy mutations. J Med Genet 26:553–559 (1989).
5.
Bakker E, Wijmenga C, Vossen RH, Padberg GW, Hewitt J, et al: The FSHD-linked locus D4F104S1 (p13E-11) on 4q35 has a homologue on 10qter. Muscle Nerve 2:S39–44 (1995).
6.
Ballif BC, Rorem EA, Sundin K, Lincicum M, Gaskin S, et al: Detection of low-level mosaicism by array CGH in routine diagnostic specimens. Am J Med Genet 140:2757–2767 (2006).
7.
Bluth MH, Reid ME, Manny N: Chimerism in the immunohematology laboratory in the molecular biology era. Transfus Med Rev 21:134–146 (2007).
8.
Bruder CE, Piotrowski A, Gijsbers AA, Andersson R, Erickson S, et al: Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet 82:763–771 (2008).
9.
Bustamante C, Gurrieri S, Smith SB: Towards a molecular description of pulsed-field gel electrophoresis. Trend Biotech 11:23–30 (1993).
10.
Campbell PJ, Stephens PJ, Pleasance ED, O’Meara S, Li H, et al: Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet 40:722–729 (2008).
11.
Carter NP: Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 39:S16–21 (2007).
12.
Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. Nature 395:89–93 (1998).
13.
Cheung SW, Shaw CA, Scott DA, Patel A, Sahoo T, et al: Microarray-based CGH detects chromosomal mosaicism not revealed by conventional cytogenetics. Am J Med Genet 143:1679–1686 (2007).
14.
den Dunnen JT, Bakker E, Breteler EG, Pearson PL, van Ommen GJ: Direct detection of more than 50% of the Duchenne muscular dystrophy mutations by field inversion gels. Nature 329:640–642 (1987).
15.
den Dunnen JT, Grootscholten PM, Bakker E, Blonden LA, Ginjaar HB, et al: Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 45:835–847 (1989).
16.
den Dunnen JT, Grootscholten PM, Dauwerse JG, Walker AP, Monaco AP, et al.: Reconstruction of the 2.4 Mb human DMD-gene by homologous YAC recombination. Hum Mol Genet 1:19–28 (1992).
17.
Erickson RP: Somatic gene mutation and human disease other than cancer. Mutat Res 543:125–136 (2003).
18.
Faizunnessa NN, Tsuchiya T, Kumatori A, Kurozumi H, Imajoh-Ohmi S, et al: A 25-kb deletion in the 5′ region of the cytochrome b558 heavy chain gene (CYBB) in a patient with X-linked chronic granulomatous disease. Hum Genet 99:469–473 (1997).
19.
Forrest SM, Cross GS, Speer A, Gardner-Medwin D, Burn J, Davies KE: Preferential deletion of exons in Duchenne and Becker muscular dystrophies. Nature 329:638–640 (1987).
20.
Gervasini C, Castronovo P, Bentivegna A, Mottadelli F, Faravelli F, et al: High frequency of mosaic CREBBP deletions in Rubinstein-Taybi syndrome patients and mapping of somatic and germ-line breakpoints. Genomics 90:567–573 (2007).
21.
Hall JG: Review and hypotheses: somatic mosaicism: observations related to clinical genetics. Am J Hum Genet 43:355–363 (1988).
22.
Higuchi M, Kochhan L, Olek K: A somatic mosaic for haemophilia A detected at the DNA level. Mol Biol Med 5:23–27 (1988).
23.
Hirschhorn R: In vivo reversion to normal of inherited mutations in humans. J Med Genet 40:721–728 (2003).
24.
Janssen B, Hartmann C, Scholz V, Jauch A, Zschocke J: MLPA analysis for the detection of deletions, duplications and complex rearrangements in the dystrophin gene: potential and pitfalls. Neurogenetics 6:29–35 (2005).
25.
Kehrer-Sawatzki H, Kluwe L, Sandig C, Kohn M, Wimmer K, et al: High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene. Am J Hum Genet 75:410–423 (2004).
26.
Kenwrick S, Woffendin H, Jakins T, Shuttleworth SG, Mayer E, et al: Survival of male patients with incontinentia pigmenti carrying a lethal mutation can be explained by somatic mosaicism or Klinefelter syndrome. Am J Hum Genet 69:1210–1217 (2001).
27.
Khan F, Agarwal A, Agrawal S: Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme. Bone Marrow Transplant 34:1–12 (2004).
28.
Kidd JM, Cooper GM, Donahue WF, Hayden HS, Sampas N, et al: Mapping and sequencing of structural variation from eight human genomes. Nature 453:56–64 (2008).
29.
Kitsberg D, Selig S, Keshet I, Cedar H: Replication structure of the human beta-globin gene domain. Nature 366:588–590 (1993).
30.
Klein CJ, Coovert DD, Bulman DE, Ray PN, Mendell JR, Burghes AH: Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. Am J Hum Genet 50:950–959 (1992).
31.
Knudson RA, Shearer BM, Ketterling RP: Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 175:8–18 (2007).
32.
Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, et al: Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 121:389–400 (2007).
33.
Lazaro C, Ravella A, Gaona A, Volpini V, Estivill X: Neurofibromatosis type 1 due to germ-line mosaicism in a clinically normal father. N Engl J Med 331:1403–1407 (1994).
34.
Lemmers RJ, van der Maarel SM, van Deutekom JC, van der Wielen MJ, Deidda G, et al: Inter- and intrachromosomal sub-telomeric rearrangements on 4q35: implications for facioscapulohumeral muscular dystrophy (FSHD) aetiology and diagnosis. Hum Mol Genet 7:1207–1214 (1998).
35.
Lemmers RJ, van der Wielen MJ, Bakker E, Padberg GW, Frants RR, van der Maarel SM: Somatic mosaicism in FSHD often goes undetected. Annal Neurol 55:845–850 (2004a).
36.
Lemmers RJ, Van Overveld PG, Sandkuijl LA, Vrieling H, Padberg GW, et al: Mechanism and timing of mitotic rearrangements in the subtelomeric D4Z4 repeat involved in facioscapulohumeral muscular dystrophy. Am J Hum Genet 75:44–53 (2004b).
37.
Liehr T, Claussen U: Current developments in human molecular cytogenetic techniques. Curr Mol Med 2:283–297 (2002).
38.
Lissauer D, Piper KP, Moss PA, Kilby MD: Persistence of fetal cells in the mother: friend or foe? BJOG 114:1321–1325 (2007).
39.
Lupski JR, Stankiewicz P: Genomic disorders: molecular mechanisms for rearrangements and conveyed phenotypes. PLoS Genet 1:e49 (2005).
40.
Mandel JL: Dystrophin. The gene and its product. Nature 339:584–586 (1989).
41.
Milewicz DM, Witz AM, Smith AC, Manchester DK, Waldstein G, Byers PH: Parental somatic and germ-line mosaicism for a multiexon deletion with unusual endpoints in a type III collagen (COL3A1) allele produces Ehlers-Danlos syndrome type IV in the heterozygous offspring. Am J Hum Genet 53:62–70 (1993).
42.
Najfeld V, Burnett W, Vlachos A, Scigliano E, Isola L, Fruchtman S: Interphase FISH analysis of sex-mismatched BMT utilizing dual color XY probes. Bone Marrow Transplant 19:829–834 (1997).
43.
Passos-Bueno MR, Bakker E, Kneppers AL, Takata RI, Rapaport D, et al: Different mosaicism frequencies for proximal and distal Duchenne muscular dystrophy (DMD) mutations indicate difference in etiology and recurrence risk. Am J Hum Genet 51:1150–1155 (1992).
44.
Percy ME, Markovic VD, Dalton AJ, McLachlan DR, Berg JM, et al: Age-associated chromosome 21 loss in Down syndrome: possible relevance to mosaicism and Alzheimer disease. Am J Med Genet 45:584–588 (1993).
45.
Petek E, Jenne DE, Smolle J, Binder B, Lasinger W, et al: Mitotic recombination mediated by the JJAZF1 (KIAA0160) gene causing somatic mosaicism and a new type of constitutional NF1 microdeletion in two children of a mosaic female with only few manifestations. J Med Genet 40:520–525 (2003).
46.
Piotrowski A, Bruder CE, Andersson R, diaz de Stahl T, Menzel U, et al: Somatic mosaicism for copy number variation in differentiated tissues. Hum Mutat 29:1118–1124 (2008).
47.
Rasmussen SA, Colman SD, Ho VT, Abernathy CR, Arn PH, et al: Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1. J Med Genet 35:468–471 (1998).
48.
Repas-Humpe LM, Humpe A, Lynen R, Glock B, Dauber EM, et al: A dispermic chimerism in a 2-year-old Caucasian boy. Ann Hematol 78:431–434 (1999).
49.
Rizwana R, Hahn PJ: CpG methylation reduces genomic instability. J Cell Sci 112:4513–4519 (1999).
50.
Roberts RG, Coffey AJ, Bobrow M, Bentley DR: Exon structure of the human dystrophin gene. Genomics 16:536–538 (1993).
51.
Schinzel A: Tetrasomy 12p (Pallister-Killian syndrome). J Med Genet 28:122–125 (1991).
52.
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57 (2002).
53.
Sgambati MT, Stolle C, Choyke PL, Walther MM, Zbar B, et al: Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet 66:84–91 (2000).
54.
Shaffer LG, Bejjani BA: Medical applications of array CGH and the transformation of clinical cytogenetics. Cytogenet Genome Res 115:303–309 (2006).
55.
Sippel KC, Fraioli RE, Smith GD, Schalkoff ME, Sutherland J, et al: Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling. Am J Hum Genet 62:610–619 (1998).
56.
Smyk M, Obersztyn E, Nowakowska B, Bocian E, Cheung SW, et al: Recurrent SOX9 deletion campomelic dysplasia due to somatic mosaicism in the father. Am J Med Genet 143:866–870 (2007).
57.
Steinmann K, Cooper DN, Kluwe L, Chuzhanova NA, Senger C, et al: Type 2 NF1 deletions are highly unusual by virtue of the absence of nonallelic homologous recombination hotspots and an apparent preference for female mitotic recombination. Am J Hum Genet 81:1201–1220 (2007).
58.
Strain L, Dean JC, Hamilton MP, Bonthron DT: A true hermaphrodite chimera resulting from embryo amalgamation after in vitro fertilization. N Engl J Med 338:166–169 (1998).
59.
Tawil R, Forrester J, Griggs RC, Mendell J, Kissel J, et al: Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Annal Neurol 39:744–748 (1996).
60.
Tawil R, Figlewicz DA, Griggs RC, Weiffenbach B: Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium. Annal Neurol 43:279–282 (1998).
61.
Upadhyaya M, Maynard J, Osborn M, Jardine P, Harper PS, Lunt P: Germinal mosaicism in facioscapulohumeral muscular dystrophy (FSHD). Muscle Nerve 2:S45–49 (1995).
62.
van der Maarel SM, Deidda G, Lemmers RJ, van Overveld PG, van der Wielen M, et al: De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10. Am J Hum Genet 66:26–35 (2000).
63.
van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, et al: FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 2:2037–2042 (1993).
64.
van Ommen GJ, Breuning MH, Raap AK: FISH in genome research and molecular diagnostics. Curr Opin Genet Dev 5:304–308 (1995).
65.
Vissers LE, Veltman JA, van Kessel AG, Brunner HG: Identification of disease genes by whole genome CGH arrays. Hum Mol Genet 14 Spec No. 2:R215–223 (2005).
66.
Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, et al: The complete genome of an individual by massively parallel DNA sequencing. Nature 452:872–876 (2008).
67.
White SJ, den Dunnen JT: Copy number variation in the genome; the human DMD gene as an example. Cytogenet Genome Res 115:240–246 (2006).
68.
White SJ, Aartsma-Rus A, Flanigan KM, Weiss RB, Kneppers AL, et al: Duplications in the DMD gene. Hum Mutat 27:938–945 (2006).
69.
Wijmenga C, Hewitt JE, Sandkuijl LA, Clark LN, Wright TJ, et al: Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 2:26–30 (1992).
70.
Youssoufian H, Pyeritz RE: Mechanisms and consequences of somatic mosaicism in humans. Nat Rev 3:748–758 (2002).
71.
Yunis EJ, Zuniga J, Romero V, Yunis EJ: Chimerism and tetragametic chimerism in humans: implications in autoimmunity, allorecognition and tolerance. Immunol Res 38:213–236 (2007).
72.
Zatz M, Marie SK, Passos-Bueno MR, Vainzof M, Campiotto S, et al: High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet 56:99–105 (1995).
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.